Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?

Abstract

The immune-correlate analysis of the RV144 clinical trial revealed that human plasma IgA immune responses elicited by the RV144 vaccine correlated positively with a risk for HIV acquisition. This result once again emphasized that HIV vaccines can potentially have adverse effects leading to enhancement of infection. Here, we discuss previously reported evidence of antibody-dependent enhancement of HIV infection. We also describe how a structure-based epitope-specific sieve-analysis can be employed to mine the molecular mechanism underlying this phenomenon.

• Authors: Evgeny Shmelkov, Arthur Nadas, Timothy Cardozo
• Journal: Human vaccines & immunotherapeutics (Hum Vaccin Immunother) Vol. 10 Issue 10 Pg. 3013-6 ( 2014) ISSN: 2164-554X [Electronic] United States
• PMID: 25483466 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• AIDS Vaccines
• AIDSVAX
• HIV Antibodies
• HIV Envelope Protein gp120
• Immunoglobulin A

Topics

• AIDS Vaccines (adverse effects, immunology)
• Antibody-Dependent Enhancement (immunology)
• HIV Antibodies (immunology)
• HIV Envelope Protein gp120 (immunology)
• HIV Infections (immunology)
• HIV-1 (immunology)
• Humans
• Immunoglobulin A (immunology)
• Vaccination (adverse effects)